Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Pediatrics and family. The original article is from Gut.

Based on the title and source metadata, this appears to be a conference abstract related to Inflammatory bowel disease and Access, cost, and policy. The original article is from Gut.

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease, Imaging, and Tests and monitoring. The original article is from Gut.

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Genetics and genomics, and Research and clinical trials. The original article is from Gut.

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease, Celiac Disease, and Pediatrics and family. The original article is from Gut.

Based on the title and source metadata, this appears to be a conference abstract related to Inflammatory bowel disease and Research and clinical trials. The original article is from Gut.

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Tests and monitoring. The original article is from Gut.

Perianal fistulizing Crohn's disease causes major quality-of-life problems and is often hard to treat. This trial tests risankizumab in people who did not respond to or could not tolerate other standard therapies, and it...

The trial is testing a personalized approach that uses CLE to find foods that directly disrupt the intestinal barrier and then removes those foods to see if patients feel and biologically improve. If successful, it could...

Wearable-derived digital biomarkers could enable earlier, less burdensome detection of IBD flares and better remote monitoring if they reliably predict mucosal inflammation.

A phase 2 trial tested whether repurposing fenofibrate (a lipid-lowering PPAR-α agonist) added to mesalamine can reduce disease activity and improve quality of life in adults with mild-to-moderate ulcerative colitis.

This OLE study follows patients who lost response to ustekinumab every-8-week dosing and evaluates whether increasing to every-4-week dosing maintains efficacy and safety long-term. That question is directly relevant to...

Researchers are investigating whether a specific gut bacterium (Pilosibacter rotomagensis) is linked to lower intestinal inflammation after surgery for ileal Crohn's disease. If true, this could point toward new...

This trial tests whether adding the oral antibiotic nifuroxazide to standard mesalamine improves quality of life for people with mild-to-moderate ulcerative colitis. Results, if published, could suggest a new adjunctive...

Dietary change is a low-risk intervention many patients try; this trial specifically tested whether a gluten-free diet affects liver disease markers, intestinal inflammation, and the gut microbiome in PSC and UC...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Tests and monitoring. The original article is from CMAJ : Canadian Medical Association journal =...

Based on the title and source metadata, this appears to be a patient story related to Inflammatory bowel disease and Community and awareness. The original article is from CMAJ : Canadian Medical Association journal =...

A fungal infection (paracoccidioidomycosis) can closely mimic Crohn’s disease on clinical, endoscopic, and histologic grounds, which risks misdiagnosis and harmful treatment delays—especially in patients from endemic...

The study suggests a decade-long preclinical phase of IBD detectable by blood metabolites, which could open opportunities for earlier identification of people at risk for Crohn’s disease and for studying early disease...

This trial suggests a structured whole-food diet may reduce subclinical intestinal inflammation (measured by fecal calprotectin) in asymptomatic children and young adults with Crohn's disease—offering a non-formula,...

Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Upadacitinib, and Tofacitinib.

The study suggests L‑proline can reduce colitis in a mouse model and reshapes the gut microbiome, raising the possibility that amino-acid–based dietary strategies might influence intestinal inflammation through...

Structured mentorship and leadership programmes can affect training quality, multidisciplinary care, and service development in gastroenterology—including care areas important to people with IBD. Improvements in training...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Patient Related Outcome...

People with ulcerative colitis may be interested because the study explores a way to boost curcumin’s activity and suggests gut microbiota changes could underlie protection against colitis.

Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for...

Holiday-related stress, disrupted routines, and dietary changes can increase the chance of IBD symptom flares. Simple, practical steps can reduce stress and help maintain symptom control during the season.

A positive pre‑IND response from the FDA makes it more likely this stem‑cell therapy will reach a formal Phase 2 trial, which could eventually expand treatment options for people with refractory or fistulising Crohn’s...

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Fistula and Research and clinical trials.

If true, the finding explains why symptoms can return after remission: the gut lining may remain biologically vulnerable even when inflammation seems controlled. That could point to new approaches aimed at 'molecular...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.

Cure8 could only read part of this source from Endoscopy, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring.

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications.

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from seekingalpha.com.

The study suggests B cells can protect against colitis through secretory IgA that reshapes the gut microbiota, a mechanism separate from known regulatory B cell cytokines. This could point to new directions for IBD...

This review addresses whether people with IBD face higher breast cancer risk and how treatments for one disease might affect the other—questions many patients and clinicians raise when cancer and IBD overlap.

Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be...

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Long-term (3-year) data on a biologic for Crohn's disease may indicate how durable treatment benefits and steroid-free remission can be for people considering or already on biologic therapy.

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer...

Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...

Based on the title and source metadata, this appears to be a patient story related to Crohn's disease and Community and awareness. The original article is from sports.yahoo.com.

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease, Drug Discovery, and Research and clinical trials. The original article is from Molecular Biology Reports.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Mesalamine. The original article is from Drugs - Real World Outcomes.

Perianal Crohn’s disease causes major symptoms and affects long-term outcomes; understanding surgical options and the role of combined medical–surgical care can help patients and clinicians plan treatment. The review...

Long-term control of inflammation and healing of draining fistulas are important for people with Crohn’s disease; these FORTIFY OLE analyses suggest durable benefit with risankizumab in responders through several years...